Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23295714 | 0.80 | ADORA1 (0.45) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL13317080 | 0.73 | ADORA1 (0.66) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL19411064 | 0.72 | ADORA1 (0.51) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL636328 | 0.71 | ADORA1 (0.62) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL11628053 | 0.70 | SMN1; SMN2 (0.51) | KDM4EALDH1A1L3MBTL1TP53HPGD | |
| SCHEMBL8878415 | 0.69 | MBD2 (0.48) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL12799837 | 0.69 | ATM (0.53) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL19233749 | 0.69 | ADORA1 (0.51) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL19233748 | 0.69 | ADORA1 (0.47) | ADORA1KDM4EALDH1A1L3MBTL1ADORA2B | |
| SCHEMBL18698121 | 0.69 | ADORA1 (0.44) | ADORA1KDM4EALDH1A1L3MBTL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283017-B1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-1401838-B1 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-26 | — | — | EP | disclosed |
| US-8518955-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2626360-A1 | Process for the preparation of fused pyrimidineone compounds useful as TRPV3 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-10 | — | — | US | disclosed |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-03 | — | — | US | disclosed |
| US-8119647-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2009-11-19 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| US-7476662-B2 | Substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-13 | — | — | US | disclosed |
| EP-1451196-B1 | The use of substituted tetracyclic imidazole derivatives as anti-histaminics | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | ADORA1 433/4885KDM4E 3735/4885ALDH1A1 3118/4885 |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | ADORA1 433/4885KDM4E 3735/4885ALDH1A1 3118/4885 |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | ADORA1 433/4885KDM4E 3735/4885ALDH1A1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.